Harbor Capital Advisors Inc. Has $11.68 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Harbor Capital Advisors Inc. trimmed its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 2.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 84,873 shares of the biotechnology company’s stock after selling 2,429 shares during the quarter. Harbor Capital Advisors Inc. owned 0.14% of Ascendis Pharma A/S worth $11,684,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S in the third quarter valued at $30,000. Groupama Asset Managment bought a new position in Ascendis Pharma A/S in the third quarter valued at about $60,000. GAMMA Investing LLC increased its position in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 214 shares during the period. Signaturefd LLC raised its holdings in Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 143 shares during the period.

Wall Street Analyst Weigh In

ASND has been the subject of several analyst reports. Evercore ISI lifted their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. UBS Group initiated coverage on Ascendis Pharma A/S in a research note on Tuesday. They issued a “buy” rating and a $196.00 price target on the stock. JPMorgan Chase & Co. dropped their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. Oppenheimer cut their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Finally, TD Cowen lowered their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $192.07.

Ascendis Pharma A/S Stock Down 3.6 %

Shares of NASDAQ ASND traded down $4.83 during midday trading on Friday, hitting $129.60. 120,316 shares of the company’s stock were exchanged, compared to its average volume of 352,899. The firm has a market capitalization of $7.87 billion, a PE ratio of -16.04 and a beta of 0.65. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00. The company’s 50 day moving average price is $132.53 and its 200 day moving average price is $133.60.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.